Monoclonal antibodies and method for the determination of human G-CSF

• US 5,468,846 A
• Filed: 02/22/1994
• Issued: 11/21/1995
• Est. Priority Date: 06/30/1993
• Status: Expired due to Term

• Current Assignee: Kirin-Amgen Inc. (Amgen Inc.)
• Original Assignee: Kirin-Amgen Inc. (Amgen Inc.)
• Inventors: Matsuki, Shigeru, Ichikawa, Takanori, Kuwaki, Tomoaki, Tachibana, Katsumi
• Primary Examiner(s): Scheiner, Toni R.
• Assistant Examiner(s): Parsons, Nancy J.
• Application Number:
  US08/199,493
• Time in Patent Office: 637 Days
• Field of Search: 435/7.92, 435/7.93, 435/7.94, 435/7.95, 435/70.21, 435/240.27, 436/518, 436/548, 530/388.23, 530/391.1
• US Class Current: 530/388.23
• CPC Class Codes: C07K 16/243 Colony Stimulating Factors
• CPC Class Codes: G01N 2333/535 Granulocyte CSF; Granulocyte-macrophage CSF
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/6863 Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Abstract

The present invention relates to a high affinity monoclonal antibody and to an enzyme immunoassay of human G-CSF using the antibody.

The trace amount of human G-CSF in samples such as body fluids from patients with hematological disorders can be measured without interference in the body fluids. For example, the measurable human G-CSF concentration in plasma is 0.5 pg/ml in minimum.

Claims

1. The monoclonal anti-G-CSF antibody K35-2B produced by hybridoma cell line FERM Accession No.:

BP 4340 or a G-CSF binding fragment thereof.

2. A hybridoma cell line deposited under FERM Accession No. BP-4340.